Review



human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab
    Human Primate Bcma Tnfrsf17 Biotinylated Goat Polyclonal Antibody Pab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/10__1016_slash_j__jchromb__2026__125025-45-3-14?v=R%26D+Systems
    Average 94 stars, based on 5 article reviews
    human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    bcma expression  (ATCC)
    99
    ATCC bcma expression
    Bcma Expression, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/us12540190-267-52-63?v=ATCC
    Average 99 stars, based on 1 article reviews
    bcma expression - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    bcma  (Miltenyi Biotec)
    94
    Miltenyi Biotec bcma
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Bcma, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pmc12894375-31-9-19?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    bcma - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    b cell maturation antigen bcma ×cd3 bispecific antibody wvt078  (Novartis)
    86
    Novartis b cell maturation antigen bcma ×cd3 bispecific antibody wvt078
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    B Cell Maturation Antigen Bcma ×Cd3 Bispecific Antibody Wvt078, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pm41880322-9-12-0?v=Novartis
    Average 86 stars, based on 1 article reviews
    b cell maturation antigen bcma ×cd3 bispecific antibody wvt078 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    ab 2942102  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc ab 2942102
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Ab 2942102, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pm41864339-67-38-44?v=Cell+Signaling+Technology+Inc
    Average 94 stars, based on 1 article reviews
    ab 2942102 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    control antibody bcma igg1  (Innate Pharma)
    86
    Innate Pharma control antibody bcma igg1
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Control Antibody Bcma Igg1, supplied by Innate Pharma, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pmc13006415-98-0-3?v=Innate+Pharma
    Average 86 stars, based on 1 article reviews
    control antibody bcma igg1 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab  (R&D Systems)
    94
    R&D Systems human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Human Primate Bcma Tnfrsf17 Biotinylated Goat Polyclonal Antibody Pab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/10__1016_slash_j__jchromb__2026__125025-45-3-14?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    human primate bcma tnfrsf17 biotinylated goat polyclonal antibody pab - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    bcma antibody e6d7b  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc bcma antibody e6d7b
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Bcma Antibody E6d7b, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pm41703032-77-1-3?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    bcma antibody e6d7b - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti bcma mcc dm1  (Amgen)
    86
    Amgen anti bcma mcc dm1
    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) <t>BCMA</t> expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.
    Anti Bcma Mcc Dm1, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+bcma/pm41683862-180-9-4?v=Amgen
    Average 86 stars, based on 1 article reviews
    anti bcma mcc dm1 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) BCMA expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.

    Journal: Frontiers in Immunology

    Article Title: Tailored strategies for improved control of CAR-T cells in multiple myeloma

    doi: 10.3389/fimmu.2026.1740345

    Figure Lengend Snippet: Efficiency of ADCC and ADC on SLAMF7 and CD19 CAR-T cells in vitro ; (A) Schematic depiction of EGFR-specific ADCC; (B, C) CD19 and SLAMF7 CAR-T cells (CD4:CD8 1:1) were incubated with EGFR antibody cetuximab [50 µg/ml] and cocultured with effector cells (CFSE stained, PBMC w./w.o. NK cells, E:T 50:1 and NK cells, E:T 10:1) for 24 h, CAR-T cell elimination through ADCC is dependent on NK cell availability and CAR-T cell construct, Representative Flow cytometry plots (B) and statistical analysis ((C) n=3) are shown; (D) Lymphocyte (n=12) and NK cell (n=8) counts are reduced after lymphodepleting chemotherapy (d-5, -4 and -3) and only gradually recover; (E) Schematic depiction of the ADC assay; (F) BCMA expression of targeted cells via flow cytometry, (G, H) Cells expressing BCMA or not, were incubated with BCMA targeting ADC belantamab-mafodotin [50 µg/ml]; SLAMF7 CAR-T cells, UTD ctrl T cells (72 h; (G) ) and the human MM cell line OPM-2 (48 h & 72 h; (H) ) are shown; Control antibody: Human IgG1 Isotype Control; n=3 independent donors; Each experiment was performed in triplicates; Two-way ANOVA statistic test was performed using GraphPad Prism 9; Abbreviations: ADC, Antibody-drug conjugate; ADCC, Antibody-dependent cell cytotoxicity; ALC, Absolute Lymphocyte Count; CAR, Chimeric antigen receptor; Ctrl, Control; MM, Multiple myeloma; SLAMF7, SLAM Family member 7 (CD319); UTD, Untransduced. **** = P ≤ 0,0001; *** = P ≤ 0,001; * = P ≤ 0,05.

    Article Snippet: Antibodies used in this research report were specific for BCMA-Antibodies used in this research report were specific for BCMA (Miltenyi Biotec; 130-119-152), EGFR (Cetuximab, in-house labelled), CD8 (Miltenyi Biotec; 130-110-683) and CD4 (Miltenyi Biotec; 130-114-534).

    Techniques: In Vitro, Incubation, Staining, Construct, Flow Cytometry, Expressing, Control